3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
8
Neoplasms
5
Lymphoma, Mantle-Cell
4
Breast Neoplasms
4
Kidney Neoplasms
3
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma
2
Urogenital Neoplasms
1
Solid Tumors
1
Prostatic Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Adenocarcinoma
1
Interventions
Mitomycin
3
Abiraterone Acetate
3
motexafin gadolinium
2
abiraterone
2
Suspensions
2
Sunitinib
2
Powders
2
Paclitaxel
2
Gemcitabine
2
Drug Therapy
2
Docetaxel
2
vinflunine
1
valrubicin
1
temsirolimus
1
sipuleucel-T
1
pembrolizumab
1
palbociclib
1
onapristone
1
olaparib
1
niraparib
1
luprolide acetate gel depot
1
gallium 68 PSMA-11
1
enfortumab vedotin
1
darolutamide
1
atezolizumab
1
apalutamide
1
abemaciclib
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urogenital Neoplasms
×
temsirolimus
×
Clear all
NCT00631371
2016-04-27
INTORACT
Pfizer
Phase 3
Completed
791 enrolled
11 charts